Overview

• Sana Biotechnology Q3 net loss of $42.2 mln, with operating expenses of $43.5 mln

• Raised $115.8 mln from stock sales, cash position at $153.1 mln

• Company prioritizes SC451 and SG293, suspends other CAR T programs

Result Drivers

• TYPE 1 DIABETES FOCUS - Sana prioritizes SC451 development due to promising clinical results and regulatory progress

• R&D expenses were $35.5 million for the three ended September 30, 2025, compared to $12.4 million for the same periods in 2024

• Cash, cash equivalents, and marketable securities as of September 30, 2025 were $153.1 million compared to $152.5 million as of December 31, 2024.

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Sana Biotechnology Inc is $8.00, about 49% above its November 5 closing price of $4.08

Press Release: ID:nGNXb0j1P2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)